Dr Reddy's Laboratories has reduced the price of its cardiovascular drug Cidmus. The drug comprises combination of sacubitril and valsartan and is indicated for heart failure patients. The company's Cidmus tablets are available in three strengths - 50mg, 100mg and 200mg, to be taken twice a day.
Following the price reduction, Cidmus will be priced at Rs 29 for 50 mg (down from Rs 78.32); Rs 49 for 100 mg (down from Rs 83.86); Rs 79 for 200 mg (down from Rs 96.71) per tablet. This price reduction will further widen access to this trusted and established brand. Dr Reddy's acquired the Cidmus brand from Novartis AG in 2022 for the India market.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
| Company Name | CMP |
|---|---|
| Sun Pharma. Inds. | 1862.15 |
| Dr. Reddys Labs. | 1350.00 |
| Cipla | 1440.30 |
| Zydus Lifesciences | 1101.50 |
| Lupin | 2342.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: